LYNPARZA (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer

LYNPARZA (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer


Patients are selected for therapy based on an approved companion diagnostic. Dave Fredrickson, executive vice president, head of the oncology business unit at AstraZeneca, said, "Earlier this year, LYNPARZA became the first PARP inhibitor available in Japan for advanced ovarian cancer.



from Biotech News